Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1774 plus cemiplimab in non-squamous NSCLC after PD-(L)1 and platinum
CTR20242324Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvusertib, cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Jul 2024; status: terminated.
02
Drugs
tuvusertibcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242324.